MYCOBUTIN

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Estonia, Hong Kong SAR China, Ireland, Israel, Japan, Netherlands, New Zealand, Nigeria, South Africa, Turkey, UK.

Active ingredients

The drug MYCOBUTIN contains one active pharmaceutical ingredient (API):

1	Rifabutin UNII 1W306TDA6S - RIFABUTIN
	Rifabutin is an antibiotic used to treat tuberculosis and prevent and treat Mycobacterium avium complex.
	Read more about Rifabutin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MYCOBUTIN Capsules	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J04AB04	Rifabutin	J Antiinfectives for systemic use → J04 Antimycobacterials → J04A Drugs for treatment of tuberculosis → J04AB Antibiotics
Discover more medicines within J04AB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	6195C, 9541E
CA	Health Products and Food Branch	02063786
EE	Ravimiamet	1654635
GB	Medicines & Healthcare Products Regulatory Agency	40846
HK	Department of Health Drug Office	38559
IE	Health Products Regulatory Authority	64723
IL	מִשְׂרַד הַבְּרִיאוּת	3115
JP	医薬品医療機器総合機構	6169001M1026
NG	Registered Drug Product Database	A4-4726
Switch country to Nigeria in order to find specific presentations of MYCOBUTIN
NL	Z-Index G-Standaard, PRK	43060
NZ	Medicines and Medical Devices Safety Authority	6723
TR	İlaç ve Tıbbi Cihaz Kurumu	8681308151094
US	FDA, National Drug Code	0013-5301
ZA	Health Products Regulatory Authority	Z/20.1.1/395